Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Editorial

Cardiac troponin testing: Goodbye, ‘troponinemia’

Anirudh Kumar, MD, Divyang R. Patel, MD and Venugopal Menon, MD
Cleveland Clinic Journal of Medicine August 2020, 87 (8) 483-484; DOI: https://doi.org/10.3949/ccjm.87a.20013
Anirudh Kumar
Fellow, Heart, Vascular, and Thoracic Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Divyang R. Patel
Fellow, Heart, Vascular, and Thoracic Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venugopal Menon
Mehdi Razavi, MD, Education Endowed Chair; Director, Cardiac Intensive Care Unit; Director, Cardiovascular Fellowship, Associate Director, C5, Heart, Vascular, and Thoracic Institute, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Info & Metrics
  • PDF
Loading

The way we stratify risk for patients with chest pain suspected to arise from an acute coronary syndrome has rapidly evolved, thanks to higher cardiac troponin assay precision and sensitivity.1,2 Because fewer than 10% of patients in whom acute coronary syndrome is suspected actually have a myocardial infarction,3 algorithms using high-sensitivity assays have the potential to improve triage and reduce the costs associated with unnecessary hospital admissions and longer emergency department observation. The 2019 Fourth Universal Definition of Myocardial Infarction recommends using high-sensitivity cardiac troponin assays and has proposed criteria for further classifying patients with myocardial injury vs infarction.4

See related article, page 480

In this issue, Anderson and colleagues5 advocate against continuing to measure serial cardiac troponin levels after the diagnosis of acute coronary syndrome is established. Doing so lacks clinical utility and results in significant waste without improving patient care. We wholeheartedly agree with their plea.

The COMPASS-MI project (Calculation of Myocardial Infarction Risk Probabilities to Manage Patients With Suspicion of Myocardial Infarction)6 examined cardiovascular risk assessment based on cardiac troponin concentration, change in troponin level, and timing of resampling. Patients deemed to be at high risk based on their troponin level and absolute change during serial sampling had a significantly higher incidence of myocardial infarction and death. Of note, this determination was made using a 2-sample strategy, with the second sample obtained either early (45–120 minutes) or late (> 120–210 minutes) after the baseline sample.

THREE CLINICAL BUCKETS

Measuring cardiac troponin twice (at baseline and then either 1 hour or 3 hours later, using a high-sensitivity assay) enables clinicians to place most patients with chest pain into 1 of 3 clinical “buckets.”

Not acute coronary syndrome. Most patients fall into this category, having normal troponin levels, no increase in troponin level, and no other criteria for acute coronary syndrome. With the diagnosis ruled out, they can be safely discharged from the emergency department with minimal risk of acute ischemic complications or death. However, it is critical that other life-threatening causes of chest pain such as acute aortic dissection, pulmonary embolism, and pneumothorax be considered before this determination is made.

Definite acute coronary syndrome. At the other extreme, a minority of patients present with either established ST-elevation myocardial infarction on electrocardiography or marked elevations in troponin, which rules them in for significant acute myocardial injury. The higher the troponin level, the more likely ischemia or myocarditis is the cause of the chest pain, and admission would be warranted regardless of underlying mechanism.

Possible acute coronary syndrome. The challenge for a clinician is when troponin levels are in the intermediate range and the cause and nature of the elevation are uncertain. In particular, is the cause type 1 myocar dial infarction (due to arterial occlusion), or is it type 2 (due to supply-demand mismatch), and is it an acute or a chronic injury? And the optimal strategy for further evaluation is not well defined.

Sometimes trivialized with the terms “troponinemia” or “troponinitis,” troponin elevation that is not obviously associated with a diagnosis should not be dismissed as clinically irrelevant. To establish a diagnosis and determine further care, the clinical presentation and troponin findings must be integrated, and a judgment on the mechanism of myocardial injury must be made. However, further serial troponin testing is unlikely to benefit this group.

The High-STEACS trial (High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome)7 assessed whether implementing high-sensitivity cardiac troponin testing and the recommendations of the Universal Definition of Myocardial Infarction led to changes in investigation, treatment, and outcomes in patients stratified according to the proposed diagnostic classification. The strategy led to increases in the diagnosis of type 1 myocardial infarction, type 2 myocardial infarction, and acute and chronic myocardial injury. Unfortunately, although the strategy “identified patients at high risk of cardiovascular and noncardiovascular events [it was] not associated with consistent increases in treatment or improved outcomes.”7 The investigators concluded by calling for trials of secondary prevention to determine whether this risk is modifiable in patients without type 1 myocardial infarction.

In conclusion, a 2-sample algorithm for high-sensitivity cardiac troponin testing is a powerful and rapidly evolving tool for determining risk of future cardiovascular events and all-cause mortality. It has introduced an important shift not only in understanding the degree and trend of troponin elevation, but also in acknowledging that any elevation is prognostically important regardless of the etiology. Dismissing troponin elevations as “troponinemia” no longer appears to be a viable strategy, and appropriate attention is needed to best assess cardiovascular and noncardiovascular risk.

  • Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Bularga A,
    2. Lee KK,
    3. Stewart S, et al
    . High-sensitivity troponin and the application of risk stratification thresholds in patients with suspected acute coronary syndrome. Circulation 2019; 140(19): 1557–1568. doi: 10.1161/CIRCULATIONAHA.119.042866
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chapman AR,
    2. Lee KK,
    3. McAllister DA, et al
    . Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA 2017; 318(19): 1913–1924. doi: 10.1001/jama.2017.17488
    OpenUrlCrossRefPubMed
  3. ↵
    1. Goodacre S,
    2. Cross E,
    3. Arnold J,
    4. Angelini K,
    5. Capewell S,
    6. Nicholl J
    . The health care burden of acute chest pain. Heart 2005; 91(2):229–230. doi: 10.1136/hrt.2003.027599
    OpenUrlFREE Full Text
  4. ↵
    1. Thygesen K,
    2. Alpert JS,
    3. Jaffe AS, et al; ESC Scientific Document Group
    . Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J 2019; 40(3): 237–269. doi: 10.1093/eurheartj/ehy462
    OpenUrlCrossRefPubMed
  5. ↵
    1. Anderson N,
    2. Ives ST,
    3. Carlson MD,
    4. Apple F
    . Should cardiac troponin be monitored until a peak value is reached when evaluating for acute coronary syndrome? Cleve Clin J Med 2020; 87(8):480–482. doi: 10.3949/ccjm.87a.18125
    OpenUrlFREE Full Text
  6. ↵
    1. Neumann JT,
    2. Twerenbold R,
    3. Ojeda F, et al
    . Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med 2019; 380(26): 2529–2540. doi: 10.1056/NEJMoa1803377
    OpenUrlCrossRefPubMed
  7. ↵
    1. Chapman AR,
    2. Adamson PD,
    3. Shah ASV, et al; High-STEACS Investigators
    . High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation 2020; 141(3): 161–171. doi: 10.1161/CIRCULATIONAHA.119.042960
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (8)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiac troponin testing: Goodbye, ‘troponinemia’
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cardiac troponin testing: Goodbye, ‘troponinemia’
Anirudh Kumar, Divyang R. Patel, Venugopal Menon
Cleveland Clinic Journal of Medicine Aug 2020, 87 (8) 483-484; DOI: 10.3949/ccjm.87a.20013

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cardiac troponin testing: Goodbye, ‘troponinemia’
Anirudh Kumar, Divyang R. Patel, Venugopal Menon
Cleveland Clinic Journal of Medicine Aug 2020, 87 (8) 483-484; DOI: 10.3949/ccjm.87a.20013
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • THREE CLINICAL BUCKETS
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Should we monitor troponin up to peak value when evaluating for acute coronary syndrome?
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The beat goes on: Highlights from the new American and European A-fib guidelines
  • Subclinical hypothyroidism: What’s in a name?
  • Heart to heart: Progress in cardiovascular disease prevention for people living with HIV
Show more Editorial

Similar Articles

Subjects

  • Cardiology
  • Emergency Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire